These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31631389)

  • 41. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
    Uzawa A; Kuwabara S
    Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Köhlmeier-Degos Disease (malignant atrophic papulosis) and neurologic involvement.
    Slaviero F; Annes RD; Frighetto L; Schirmer LM; Vanzin JR; Fröhlich AC; Ferraz J; Azambuja ND
    Arq Neuropsiquiatr; 2009 Sep; 67(3A):692-4. PubMed ID: 19722051
    [No Abstract]   [Full Text] [Related]  

  • 43. Lack of recurrence of malignant atrophic papulosis of Degos in multivisceral transplant: insights into possible pathogenesis?
    Passarini B; Balestri R; D'Errico A; Pinna AD; Infusino SD
    J Am Acad Dermatol; 2011 Aug; 65(2):e49-e50. PubMed ID: 21763549
    [No Abstract]   [Full Text] [Related]  

  • 44. A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab.
    Schutgens RE; Pruissen-Peeters KA; Muus P
    Thromb Haemost; 2011 Aug; 106(2):383-5. PubMed ID: 21655680
    [No Abstract]   [Full Text] [Related]  

  • 45. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Case of Malignant Atrophic Papulosis With Multiple Complications.
    Wang H; Zhang X
    Am J Gastroenterol; 2021 Nov; 116(11):2164. PubMed ID: 34074813
    [No Abstract]   [Full Text] [Related]  

  • 49. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eculizumab in refractory myasthenic crisis.
    Yeo CJJ; Pleitez MY
    Muscle Nerve; 2018 Aug; 58(2):E13-E15. PubMed ID: 29524335
    [No Abstract]   [Full Text] [Related]  

  • 51. Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication.
    Roy B; Nowak RJ
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):63-64. PubMed ID: 32833730
    [No Abstract]   [Full Text] [Related]  

  • 52. Pediatric Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab.
    Oulego-Erroz I; Martínez-Sáenz de Jubera J; Ocaña-Alcober C; Regueras-Santos L; Ferrero-De la Mano L; Martínez-Badás JP
    Am J Respir Crit Care Med; 2021 Mar; 203(5):640-642. PubMed ID: 33142067
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of Hyperhemolysis in β-thalassemia With Multiple Immunosuppressives, Including Complement Blockade.
    Zanetti RC; Vasta LM; Romanelli K; Newton TC
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1145-e1147. PubMed ID: 33480648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab.
    Morales E; Rabasco C; Gutierrez E; Praga M
    Transpl Int; 2015 Jul; 28(7):878-80. PubMed ID: 25712140
    [No Abstract]   [Full Text] [Related]  

  • 57. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 58. [Use of prostaglandins in extracorporeal circulation and hemodialysis].
    Zaorska B
    Pol Tyg Lek; 1981 Jun; 36(23):857-60. PubMed ID: 7024949
    [No Abstract]   [Full Text] [Related]  

  • 59. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
    Jan AS; Hosing C; Aung F; Yeh J
    Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A; Devillard N; Frémeaux-Bacchi V; Hummel A; Salomon L; Contin-Bordes C; Gomer H; Legendre C; Delmas Y
    Nephrol Dial Transplant; 2016 Dec; 31(12):2122-2130. PubMed ID: 27587606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.